Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382196 | 1.00 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL3863813 | 1.00 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA | |
| Hydrochloric Acid SCHEMBL20238422 | 0.98 | ESR1 (0.45) | ESR1TSHRACHESCN4AMAOA | |
| Hydrochloric Acid SCHEMBL4935577 | 0.98 | ESR1 (0.45) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL3678678 | 0.85 | TSHR (0.44) | TSHRMAOASLC6A4 | |
| SCHEMBL5147323 | 0.83 | ADRA2A (0.39) | ESR1TSHRSCN4AMAOAMAOB | |
| SCHEMBL15295186 | 0.83 | ESR1 (0.43) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL15295134 | 0.83 | ESR1 (0.43) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL7591099 | 0.82 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA | |
| SCHEMBL28448173 | 0.82 | ESR1 (0.46) | ESR1TSHRACHESCN4AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250230-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123371-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-7576234-B2 | Michael-type addition of a nucleophile to a dialkyl 2-methylidenylpropan-1,3-dioate and the conversion of a ester moiety into an amino moiety; S)-2-methylcysteine; desferrithiocin | GENZYME CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1529037-B1 | SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | GENZYME CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080255081-A1 | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7285676-B2 | Synthesis of chiral 2-alkyl amino acids | GENZYME CORPORATION (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285670-B2 | Synthesis of substituted thiazoline carboxylic acids | GENZYME CORPORATION (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GIMI RAYOMAND H | 2006-12-14 | — | — | US | disclosed |
| US-20060235026-A1 | Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2006-10-19 | — | — | US | disclosed |
| US-20040077658-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-04-22 | — | — | US | disclosed |
| US-20040044220-A1 | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin | UNIVERSITY OF FLORIDA | 2004-03-04 | — | — | US | disclosed |
| US-20040024224-A1 | Synthesis of 2-alkyl amino acids | GENZYME CORPORATION (US) | 2004-02-05 | — | — | US | disclosed |
| US-20040006224-A1 | Synthesis of 2-alkyl amino acids | GENZYME CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | GENZYME CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | GENZYME CORPORATION | 2003-12-25 | — | — | US | disclosed |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | GENZYME CORPORATION | 2003-12-11 | — | — | US | disclosed |
| US-20030225287-A1 | Synthesis of chiral 2-alkyl amino acids | GENZYME CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225287-A1 | Synthesis of chiral 2-alkyl amino acids | FTH1, CISD2, PTMS | ESR1 4183/4885TSHR 220/4885ACHE 4735/4885 |
| US-20030236404-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | ESR1 4055/4885TSHR 1787/4885ACHE 4032/4885 |
| US-20030236435-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline ester | FTH1, TFRC, CNDP2 | ESR1 2636/4885TSHR 178/4885ACHE 4134/4885 |
| US-20060235026-A1 | Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | CNR1, HRH4, HRH3 | ESR1 1698/4885TSHR 325/4885ACHE 3787/4885 |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | ESR1 3145/4885TSHR 631/4885ACHE 4209/4885 |
| US-20030229231-A1 | Synthesis of 2-alkylcysteine | FTH1, CISD2, CNDP2 | ESR1 4470/4885TSHR 499/4885ACHE 4735/4885 |
| US-20040044220-A1 | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin | TXNRD2, PRDX3, SOD1 | ESR1 3777/4885TSHR 977/4885ACHE 4255/4885 |
| US-20040024224-A1 | Synthesis of 2-alkyl amino acids | PTMS, DNPEP, CNDP2 | ESR1 4331/4885TSHR 728/4885ACHE 4844/4885 |
| US-20040077658-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | ESR1 4012/4885TSHR 556/4885ACHE 4183/4885 |
| US-20080255081-A1 | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin | TXNRD2, PRDX3, SOD1 | ESR1 3777/4885TSHR 977/4885ACHE 4255/4885 |
| US-20040006224-A1 | Synthesis of 2-alkyl amino acids | ASNS, AAAS, FTH1 | ESR1 3774/4885TSHR 399/4885ACHE 4802/4885 |
| US-20030236434-A1 | Synthesis of 2-alkylcysteine via substituted thiazoline amide | CNDP2, FTH1, PTMS | ESR1 3601/4885TSHR 485/4885ACHE 3826/4885 |
| US-20060281926-A1 | Synthesis of 2-alkylcysteine via phase transfer catalysis | DIMT1, ICMT, CNDP2 | ESR1 4055/4885TSHR 1787/4885ACHE 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.